A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

NCT03370302 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
28
Enrollment
INDUSTRY
Sponsor class

Stopped More favorable safety profile was observed in QD schedule, therefore further enrollment in QW schedule was terminated.

Conditions

Interventions

Sponsor

Calithera Biosciences, Inc